WO2005084306A3 - Immunogenic compositions for chlamydia pneunomiae - Google Patents

Immunogenic compositions for chlamydia pneunomiae Download PDF

Info

Publication number
WO2005084306A3
WO2005084306A3 PCT/US2005/006588 US2005006588W WO2005084306A3 WO 2005084306 A3 WO2005084306 A3 WO 2005084306A3 US 2005006588 W US2005006588 W US 2005006588W WO 2005084306 A3 WO2005084306 A3 WO 2005084306A3
Authority
WO
WIPO (PCT)
Prior art keywords
chlamydia
pneunomiae
immunogenic compositions
individual
autotransporter
Prior art date
Application number
PCT/US2005/006588
Other languages
French (fr)
Other versions
WO2005084306A2 (en
Inventor
Guido Grandi
Giulio Ratti
Original Assignee
Chiron Corp
Guido Grandi
Giulio Ratti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Guido Grandi, Giulio Ratti filed Critical Chiron Corp
Priority to EP05724183A priority Critical patent/EP1729800A4/en
Priority to JP2007501899A priority patent/JP2007526318A/en
Priority to CA002557353A priority patent/CA2557353A1/en
Priority to RU2006134631/13A priority patent/RU2006134631A/en
Priority to BRPI0508365-6A priority patent/BRPI0508365A/en
Publication of WO2005084306A2 publication Critical patent/WO2005084306A2/en
Publication of WO2005084306A3 publication Critical patent/WO2005084306A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to polypeptides for use as an autotransporter antigen. The invention further relates to methods and uses of a polypeptide for an autotransporter function in preparation of a medicament for the prevention or treatment of a Chlamydia pneumoniae infection or for the preparation of an assay for the diagnosis of a Chlamydia pneumoniae infection in an individual. Also, a method is provided for raising an immune response in an individual by administering to the individual a polypeptide for use as an autotransporter antigen.
PCT/US2005/006588 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae WO2005084306A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05724183A EP1729800A4 (en) 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae
JP2007501899A JP2007526318A (en) 2004-03-02 2005-03-02 Immunogenic composition against Chlamydiapneumoniae
CA002557353A CA2557353A1 (en) 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae
RU2006134631/13A RU2006134631A (en) 2004-03-02 2005-03-02 IMMUNOGENIC COMPOSITIONS AGAINST CHLAMIDIA PNEUMONIAE
BRPI0508365-6A BRPI0508365A (en) 2004-03-02 2005-03-02 immunogenic compositions for chlamydia pneumoniae

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54983204P 2004-03-02 2004-03-02
US60/549,832 2004-03-02
US64311005P 2005-01-12 2005-01-12
US60/643,110 2005-01-12
US64455205P 2005-01-19 2005-01-19
US60/644,552 2005-01-19

Publications (2)

Publication Number Publication Date
WO2005084306A2 WO2005084306A2 (en) 2005-09-15
WO2005084306A3 true WO2005084306A3 (en) 2006-05-26

Family

ID=34923269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006588 WO2005084306A2 (en) 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae

Country Status (6)

Country Link
EP (1) EP1729800A4 (en)
JP (1) JP2007526318A (en)
BR (1) BRPI0508365A (en)
CA (1) CA2557353A1 (en)
RU (1) RU2006134631A (en)
WO (1) WO2005084306A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ES2385045T3 (en) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Urotogenic Escherichia coli immunogens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2010009494A1 (en) * 2008-07-25 2010-01-28 Cellestis Limited A diagnostic method
JP2012502972A (en) 2008-09-18 2012-02-02 ノバルティス アーゲー Combination of vaccine adjuvant
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
JP2013532008A (en) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
ES2458355T3 (en) 2010-09-01 2014-05-05 Novartis Ag Adsorption of immunopotentiators on insoluble metal salts
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
PL2822947T3 (en) 2012-03-07 2017-01-31 Glaxosmithkline Biologicals Sa Arginine salts of a tlr7 agonist
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
JP6990522B2 (en) * 2017-04-11 2022-02-03 シスメックス株式会社 A method for measuring the immune stimulus response of immune cells, a method for determining the ability of immunological synapses to form in immune cells, and a cell analyzer.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1729800A4 *

Also Published As

Publication number Publication date
BRPI0508365A (en) 2007-07-24
CA2557353A1 (en) 2005-09-15
JP2007526318A (en) 2007-09-13
RU2006134631A (en) 2008-04-10
WO2005084306A2 (en) 2005-09-15
EP1729800A2 (en) 2006-12-13
EP1729800A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
NL300897I2 (en) Neisseira meningitidis serogroup B recombinantly lipidated fHbp subfamily A05 protein
WO2006032472A3 (en) Immunogenic composition for use in vaccination against staphylococcei
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2004014418A3 (en) Neisserial vaccine compositions comprising a combination of antigens
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006042149A3 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
WO2005122741A3 (en) Antibodies against west nile virus and therapeutic and prophylactic uses thereof
WO2006078318A3 (en) Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006104890A3 (en) Vaccines against chlamydial infection
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2006004390A3 (en) Preparation and use of a bivalent vaccine against morphine-heroin addiction
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2003059385A3 (en) Hiv vaccine and method of use
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2006007555A3 (en) Rotavirus antigens
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2009005040A1 (en) Pseudomonas aeruginosa outer membrane protein pa4710
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2557353

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007501899

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010041

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005724183

Country of ref document: EP

Ref document number: 2006134631

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580013852.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005724183

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508365

Country of ref document: BR